Author: admin

Revolutionizing Outdoor Hydration: Glacier Fresh Debuts OSMOGO RV RO Water Purifier for Clean, Safe Water Anywhere

NewYork, North America – August 15, 2025 – Glacier Fresh, a leader in innovative water filtration solutions, today announced the launch of its groundbreaking OSMOGO RV Reverse Osmosis (RO) System, designed to empower full-time RVers, van lifers, and off-grid adventurers with pure, safe drinking water no matter where their journey takes them. This compact, powerful system shatters the limitations of traditional RV water filtration.

The Untamed Challenge: Why Outdoor Safety Needs Reinvention

For decades, outdoor hydration relied on compromises:

  • Boiling & Chemicals: Time-consuming and ineffective against heavy metals like lead or arsenic.

  • Bottled Water: Environmentally catastrophic (480 billion plastic bottles discarded yearly) and impractical for extended trips.

  • Standard Filters: Limited to sediment and bacteria, failing against viruses or dissolved toxins.

“Clean streams can hide E. coli, giardia, or industrial runoff. A 24-hour illness in cities becomes a crisis in the backcountry”, notes Glacier Fresh`s Chief Engineer, Alex Chen, reflecting on 3 years of field research.

Meet OSMOGO: The Ultra-Portable RV Reverse Osmosis System

Uniquely among camping filters, OSMOGO RV water purifier employs a true reverse-osmosis membrane stage – the same technology found in home RO systems – adapted for on-the-go use. Inside, the OSMOGO contains a 3-stage composite filtration system: a sediment/carbon pre-filter, a reverse-osmosis membrane, and an activated carbon post-filter.

Key features of the OSMOGO include.

  • Ultra-portable design: Weighing just a few pounds with a built-in handle, it fits into RV storage or packs.

  • USB-C Power: Runs on standard 24V DC (draws 30W) from any USB power bank or power adapter. No AC power is needed, making it ideal for boondocking.

  • Durable Outdoor Build: Engineered to work in broad conditions(4–40 °C, 5–90% humidity), its rugged shell withstands bumps and jostles common on trails.

  • High-Performance Filtration: The RO membrane blocks viruses and dissolved heavy metals, while carbon filters reduce chlorine and chemicals. Each composite filter treats 2,000-4,000 liters of water — enough for weeks of use on extended trips.

Together, these features make OSMOGO a step above conventional camping filters. Many lightweight straw or pump filters cannot stop viruses or dissolved pollutants. In contrast, OSMOGO’s RO membrane leaves virtually none of these contaminants behind. In practical terms, campers can plug it into a power bank and fill a jug from a lake or questionable spigot, then drink with confidence.

Choose OSMOGO: Advantages Over Traditional Outdoor Filters

Traditional portable filters(hollow-fiber pumps, charcoal units, UV pens, etc.) are useful but each has limits. OSMOGO`s RO-based design is a major advance that tackles nearly all common contaminants:

  • Pathogen Removal: Removes bacteria, parasites and viruses, whereas most gravity or pump filters handle only the first two. OSMOGO’s RO stage ensures the water meets strict potable standards.

  • Chemical & Metal Safety: The activated carbon layers reduce chlorine and organic chemicals, and the RO membrane rejects dissolved arsenic, lead, mercury and other toxins – feats that simple filters or chemical disinfectants alone cannot accomplish.

  • Convenience: Once set up, OSMOGO runs continuously without manual effort. Unlike slow gravity drip or manual pump systems, it provides a steady flow (about 0.26 L/min) with no pumping needed.

  • Longevity: Each filter cartridge lasts for thousands of liters. This means far fewer filter changes compared to most travel filters.

Explore OSMOGO: Real-World Use Cases

The OSMOGO RV water purifier was built to solve real travel needs:

  • Full-Time RVers & Van-Lifers: Hook it up at campgrounds or boondock sites to any faucet or hose. Even spotty or aging supplies can be purified, ensuring the RV’s onboard tank and kitchen always have safe water.

  • Off-Grid & Backcountry Adventures: Filter lake, river or rainwater while hiking, camping or overlanding. With a power bank or solar panel, even wilderness sources can become drinkable.

  • Emergency & Home Use: Acts as a reliable backup during outages or natural disasters. Any fresh water (tap, well, creek) can be filtered when supplies are interrupted. OSMOGO also doubles as a compact countertop RO system for home use, aligning with Glacier Fresh’s “total scenario freedom” concept.

These scenarios highlight OSMOGO’s adaptability: it truly delivers clean water anywhere, whether at a campsite or in the kitchen.

Expanding the Eco-system: Glacier Fresh`s Commitment to Every Hydration Scenario

While the OSMOGO RV water purifier redefines mobility, Glacier Fresh`s comprehensive product ecosystem addresses water safety across all environments.

For home and kitchen use, high-capacity tankless RO systems like the Glacier Fresh U03 Elite deliver 800 gallons per day for large households. Refrigerator-specific filters maintain mineral balance for crisp-tasting water and ice. For off-grid resilience, gravity-fed purification systems provide reliable backup during emergencies. For living room or bedroom, PURELA glass filter pitcher using recyclable glass, cutting plastic waste by 65%.

In 2025 Glacier Fresh launched an “industry-first eco filtration line,” partnering with sustainability advocates to incorporate greener materials and processes. “Our partnerships with material scientists and outdoor gear specialists prove sustainability isn`t a trade-off for performance,” states CEO William Wu.

About Glacier Fresh

Glacier Fresh is a North American leader in sustainable water purification, serving households and adventurers with NSF-certified solutions. Winner of 4 global design awards, it partners with environmental nonprofits like Polarhub to protect freshwater ecosystems. With the OSMOGO RV Water Purifier, Glacier Fresh brings its trusted RO technology outdoors, enabling travelers to hydrate safely wherever they roam.

Explore and learn more at https://glacierfreshfilter.com/.

Media Contact
Company Name: Crisol Technology Hk Limited
Contact Person: William Wu
Email: Send Email
Country: United States
Website: https://www.glacierfreshfilter.com/

Breaking Chains: A Powerful Memoir on Overcoming Religious Trauma with Faith

Anderson’s groundbreaking memoir offers a powerful narrative of personal struggle, religious trauma, and the ultimate healing found through faith and acceptance.

This compelling book is now available on Amazon. It is a great read, the book is challenging all the rigged ideas of religion. Wounded by Religion, Healed by Faith opens up a powerful, inclusive experience of faith and acceptance and love.

A Heartfelt Story of Survival and Transformation

In Wounded by Religion, Healed by Faith, Anderson gives a very raw and unflinching account of a life lived at the intersection of theology and identity released through this book in emotive storytelling around issues of guilt, rejection, and resilience, with ultimate closure in spiritual awakening. Therein lies something for every person who has been judged or excluded by church systems- a read worth all for anyone in underbelly traditions hoping for more insight and understanding through their struggles.

It talks about the journey of the protagonist as they sum up life in terms of faith and sexuality and also carry on their fight for self-acceptance in a world that hardly separates God’s love from man’s religious principles. These journeys very well demonstrate the personal strength of faith against institutional condemnation and finally unveil the liberating truth that spirituality and acceptance do belong together.

A Timely Book for an Evolving Conversation

During this time, more conversations about religious trauma, LGBTQ+ inclusion, and spiritual healing are coming to the forefront. Wounded by Religion, Healed by Faith provides a necessary perspective. It shows the way people are being hurt by religious exclusion but extends healing to all who seek it- the faith that includes rather than excludes.

Anderson states, “Mine is not just my story; this is the story of many who have faced the pain of rejection through the eyes of religion. But my experience has taught me that faith is not about being exclusive; it is about love, understanding, and establishing a deeper relationship with the divine beyond the arbitrary borders set by humankind.”

Themes Explored in the Book

• Religious Trauma & Healing: This book seeks healing from spiritual trauma by studying how rigid religious beliefs have caused emotional damage and have set an individual on a restoration path.

• Identity and Self-Acceptance: A beautiful story about being able to accept oneself no matter what society or religion says.

• Beyond-the-Church Perspective: Faith lives outside the establishment and is endorsed by personal spirituality paths toward healing.

• Guilt & Fear: The authors of fear-laden doctrines that have kept so many people from embracing their full selves.

• Love and Redemption: A celebration of the healing power of love, acceptance, and unwavering faith in a very real and loving God.

A Must-Read for Those on a Journey to Healing

This book is a must-read for:

• People who have suffered religiously traumatic experiences or have exclusionary experiences

• LGBTQ+ persons searching for an inclusive faith for their identity

• Faith leaders and faith communities desire a space that is more inclusive

• Anyone on the journey of spiritual restoration and self-discovery

• Counselors and mental health professionals working with clients suffering from faith-based trauma

Praise for Wounded by Religion, Healed by Faith

Readers have begun praising the volumes in sincere depth and transformational potential. It has been called by many as a memory-forging but eye-opening read that has the power for critical reflection regarding the ultimate meaning of faith.

“An incredibly powerful and moving book that will appeal to anybody torn between faith or religion and identity.” – Early Reader Review

“This book is a beacon of hope for individuals having difficulty reconciling who they are with what they’ve been taught. Anderson’s story is both heart-rending and inspiring.” – Literary Review.

Why This Book Matters Now More Than Ever

In a world still grappling with inclusion in religious institutions, Wounded by Religion, Healed by Faith puts forth an essential discussion on the real impacts of faith-based rejection. The text implores religious communities to embrace compassion over condemnation and challenges readers to change paradigms concerning the role that faith has in throwing deeper love and acceptance into the mix.

Anderson’s memoir illustrates how personal faith can be reclaimed and redefined, proving even the most religion-scarred can experience healing. With both a vulnerable and empowering voice, this book invites freedom from harmful beliefs and into a more authentic, spiritually abundant life.

Availability

Wounded by Religion, Healed by Faith is now available on Amazon in both paperback and Kindle editions. Readers can purchase their copy at Amazon.

Author’s Mission & Future Plans

Anderson’s mission encompasses more than this book. The true spiritual healing of inclusion is to activate conversations in religious circles around acceptance and love. Future initiatives include workshops, speaking events, and further writings on healing religious trauma and reclaiming spirituality in an affirming manner.

About the Author

Anderson is a passionate advocate for spiritual healing and inclusivity. Drawing from personal experiences, their work focuses on creating spaces where faith and self-acceptance can thrive. Through Wounded by Religion, Healed by Faith, Anderson seeks to inspire those who feel alienated by religious institutions to reclaim their spirituality and find peace on their own terms.

Media Contact
Company Name: The Empire Publishers (USA)
Contact Person: Mike Anderson and Nick Hanson
Email: Send Email
Country: United States
Website: https://www.theempirepublishers.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Breaking Chains: A Powerful Memoir on Overcoming Religious Trauma with Faith

HER2 Negative Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, HER2 Negative Breast Cancer pipeline constitutes 70+ key companies continuously working towards developing 75+ HER2 Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“HER2 Negative Breast Cancer Pipeline Insight, 2025″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HER2 Negative Breast Cancer Market.

 

The HER2 Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the HER2 Negative Breast Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel HER2 Negative Breast Cancer treatment therapies with a considerable amount of success over the years.

  • HER2 Negative Breast Cancer companies working in the treatment market are Ono Pharmaceutical Co. Ltd, BeiGene, Bristol Myers Squibb, Chia Tai Tianqing Pharmaceutical, Merck & Co, EnhancedBio Inc., Relay Therapeutics, Inc., Prelude Therapeutics, Ellipses Pharma, Beta Pharma, CytomX Therapeutics, Atossa Therapeutics, Inc, AstraZeneca, Roche, Celcuity, Inc., BeiGene, Olema Pharmaceuticals, Inc., Adagene Inc, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Genentech, and others, are developing therapies for the HER2 Negative Breast Cancer treatment

  • Emerging HER2 Negative Breast Cancer therapies in the different phases of clinical trials are- ONO 4578, BGB 43395, RYZ101, TQB2102, Belzutifan, ER-PROTAC, RLY-2608, PRT2527, EP0062, BPI-1178, CX-2009, Z-endoxifen, AZD9833, GDC-9545, Gedatolisib, BGB-290, OP-1250, AZD9833, ADG106, Dato-DXd, HRS8807, Ipatasertib, and others are expected to have a significant impact on the HER2 Negative Breast Cancer market in the coming years.

  • In January 2025, Mersana Therapeutics, Inc. reported that the US Food and Drug Administration (FDA) has granted an additional Fast Track designation to XMT-1660. This designation covers the treatment of advanced or metastatic breast cancer in patients with HER2-low (IHC 1+ or IHC 2+/ISH–) or HER2-negative (IHC 0) disease, including those with triple-negative breast cancer (TNBC).

  • In January 2025, Genentech Therapeutics’ Phase III trial evaluating Itovebi (inavolisib) in patients with specific forms of metastatic breast cancer achieved the key oncology benchmark of improved overall survival (OS), while also significantly delaying disease progression. The randomized, double-blind study (NCT04191499) further demonstrated that the combination of Itovebi with Ibrance (palbociclib) and Faslodex (fulvestrant) met a secondary endpoint by delivering a statistically significant and clinically meaningful OS benefit in patients with PIK3CA-mutated, hormone receptor-positive (HR+), and HER2-negative breast cancer.

  • In February 2025, Washington University School of Medicine is conducting a Phase Ib/II clinical trial to assess the safety and effectiveness of zunsemetinib (ATI-450) in combination with capecitabine for patients diagnosed with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).

  • In February 2025, Stemline Therapeutics Inc. is conducting a study to assess the efficacy and safety of elacestrant over a 6-month period in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer who have not previously been treated with CDK4/6 inhibitors in the metastatic setting.

  • In February 2025, Merck Sharp & Dohme LLC is conducting a study to evaluate the safety and effectiveness of belzutifan (MK-6482) in combination with fulvestrant, compared to everolimus paired with an endocrine therapy (either fulvestrant or exemestane, as selected by the investigator), in adult patients with estrogen receptor-positive, HER2-negative (ER+/HER2-) unresectable metastatic breast cancer. This trial is exploratory and does not involve formal hypothesis testing.

  • In February 2025, Puma Biotechnology Inc. is conducting PUMA-ALI-1201, a randomized, multicenter Phase 2 trial aimed at optimizing the dose of alisertib in combination with endocrine therapy for patients with confirmed HR-positive/HER2-negative metastatic breast cancer (MBC). Participants must have experienced disease progression after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. The study will determine the most effective alisertib dose in combination with a selected endocrine therapy and will also assess the combination’s efficacy, safety, and pharmacokinetics. Additionally, the trial seeks to identify biomarker-defined subgroups that may derive the greatest benefit from this therapeutic approach.

  • In February 2025, GE Healthcare is conducting a multicenter study across France to assess how ESTROTEP PET/CT imaging influences treatment decisions in patients with metastatic breast cancer (MBC). Each participant will undergo a screening process to ensure they fulfill all inclusion requirements and do not meet any exclusion conditions.

  • In December 2024, Olema Pharmaceuticals shared clinical data from its ongoing Phase Ib/II trial evaluating palazestrant in combination with ribociclib for patients with ER-positive/HER2-negative advanced or metastatic breast cancer at SABCS 2024.

 

HER2 Negative Breast Cancer Overview

HER2-negative breast cancer is a type of breast cancer that tests negative for the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a protein that promotes the growth of cancer cells, and when breast cancer is HER2-negative, it means the cancer cells do not overexpress this protein. This subtype includes hormone receptor-positive and triple-negative breast cancers. Treatment for HER2-negative breast cancer typically excludes HER2-targeted therapies and may involve hormone therapy, chemotherapy, or immunotherapy depending on the specific subtype and stage of the disease.

 

Get a Free Sample PDF Report to know more about HER2 Negative Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/her2-negative-breast-cancer-pipeline-insight

 

Emerging HER2 Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

  • ONO 4578: Ono Pharmaceutical Co. Ltd

  • BGB 43395: BeiGene

  • RYZ101: Bristol Myers Squibb

  • TQB2102: Chia Tai Tianqing Pharmaceutical

  • Belzutifan: Merck & Co

  • ER-PROTAC: EnhancedBio Inc.

  • RLY-2608: Relay Therapeutics, Inc.

  • PRT2527: Prelude Therapeutics

  • EP0062: Ellipses Pharma

  • BPI-1178: Beta Pharma

  • CX-2009: CytomX Therapeutics

  • Z-endoxifen: Atossa Therapeutics, Inc

  • GDC-9545: Roche

  • Gedatolisib: Celcuity, Inc.

  • BGB-290: BeiGene

  • OP-1250: Olema Pharmaceuticals, Inc.

  • AZD9833: AstraZeneca

  • ADG106: Adagene Inc

  • Dato-DXd: Daiichi Sankyo, Inc.

  • HRS8807: Shanghai Hengrui Pharmaceutical Co.

  • Ipatasertib: Genentech

 

HER2 Negative Breast Cancer Route of Administration

HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

HER2 Negative Breast Cancer Molecule Type

HER2 Negative Breast Cancer Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

HER2 Negative Breast Cancer Pipeline Therapeutics Assessment

  • HER2 Negative Breast Cancer Assessment by Product Type

  • HER2 Negative Breast Cancer By Stage and Product Type

  • HER2 Negative Breast Cancer Assessment by Route of Administration

  • HER2 Negative Breast Cancer By Stage and Route of Administration

  • HER2 Negative Breast Cancer Assessment by Molecule Type

  • HER2 Negative Breast Cancer by Stage and Molecule Type

 

DelveInsight’s HER2 Negative Breast Cancer Report covers around 75+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further HER2 Negative Breast Cancer product details are provided in the report. Download the HER2 Negative Breast Cancer pipeline report to learn more about the emerging HER2 Negative Breast Cancer therapies

 

Some of the key companies in the HER2 Negative Breast Cancer Therapeutics Market include:

Key companies developing therapies for HER2 Negative Breast Cancer are – Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., Modra Pharmaceuticals, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., MedImmune LLC, QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer, andn others.

 

HER2 Negative Breast Cancer Pipeline Analysis:

The HER2 Negative Breast Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Negative Breast Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Negative Breast Cancer Treatment.

  • HER2 Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • HER2 Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about HER2 Negative Breast Cancer drugs and therapies

 

HER2 Negative Breast Cancer Pipeline Market Drivers

  • HER2 protein is considered a relevant biomarker for treatment, growing prevalence of Breast Cancer are some of the important factors that are fueling the HER2 Negative Breast Cancer Market.

 

HER2 Negative Breast Cancer Pipeline Market Barriers

  • However, poor understanding in the context of breast cancer subtype, lack of research in identification of factors involved in resistance and other factors are creating obstacles in the HER2 Negative Breast Cancer Market growth.

 

Scope of HER2 Negative Breast Cancer Pipeline Drug Insight

  • Coverage: Global

  • Key HER2 Negative Breast Cancer Companies: Ono Pharmaceutical Co. Ltd, BeiGene, Bristol Myers Squibb, Chia Tai Tianqing Pharmaceutical, Merck & Co, EnhancedBio Inc., Relay Therapeutics, Inc., Prelude Therapeutics, Ellipses Pharma, Beta Pharma, CytomX Therapeutics, Atossa Therapeutics, Inc, AstraZeneca, Roche, Celcuity, Inc., BeiGene, Olema Pharmaceuticals, Inc., Adagene Inc, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Genentech, and others

  • Key HER2 Negative Breast Cancer Therapies: ONO 4578, BGB 43395, RYZ101, TQB2102, Belzutifan, ER-PROTAC, RLY-2608, PRT2527, EP0062, BPI-1178, CX-2009, Z-endoxifen, AZD9833, GDC-9545, Gedatolisib, BGB-290, OP-1250, AZD9833, ADG106, Dato-DXd, HRS8807, Ipatasertib, and others

  • HER2 Negative Breast Cancer Therapeutic Assessment: HER2 Negative Breast Cancer current marketed and HER2 Negative Breast Cancer emerging therapies

  • HER2 Negative Breast Cancer Market Dynamics: HER2 Negative Breast Cancer market drivers and HER2 Negative Breast Cancer market barriers

 

Request for Sample PDF Report for HER2 Negative Breast Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. HER2 Negative Breast Cancer Report Introduction

2. HER2 Negative Breast Cancer Executive Summary

3. HER2 Negative Breast Cancer Overview

4. HER2 Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. HER2 Negative Breast Cancer Pipeline Therapeutics

6. HER2 Negative Breast Cancer Late Stage Products (Phase II/III)

7. HER2 Negative Breast Cancer Mid Stage Products (Phase II)

8. HER2 Negative Breast Cancer Early Stage Products (Phase I)

9. HER2 Negative Breast Cancer Preclinical Stage Products

10. HER2 Negative Breast Cancer Therapeutics Assessment

11. HER2 Negative Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. HER2 Negative Breast Cancer Key Companies

14. HER2 Negative Breast Cancer Key Products

15. HER2 Negative Breast Cancer Unmet Needs

16 . HER2 Negative Breast Cancer Market Drivers and Barriers

17. HER2 Negative Breast Cancer Future Perspectives and Conclusion

18. HER2 Negative Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2 Negative Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics

Colorectal Cancer Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma, Shanghai Henlius

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Colorectal Cancer pipeline constitutes 195+ key companies continuously working towards developing 200+ Colorectal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Colorectal Cancer Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Colorectal Cancer Market.

 

The Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Colorectal Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Colorectal Cancer treatment therapies with a considerable amount of success over the years.

  • Colorectal Cancer companies working in the treatment market are Plus Therapeutics, Processa Pharmaceutic als, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmace uticals Co., Ltd., G1 Therapeutics, Amgen, Mirati Therapeutics, and others, are developing therapies for the Colorectal Cancer treatment

  • Emerging Colorectal Cancer therapies in the different phases of clinical trials are- 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR, 255, Evorpacept (ALX148), CPGJ 602 Sunshine, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others are expected to have a significant impact on the Colorectal Cancer market in the coming years.

  • In April 2025, Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company specializing in PLK1 inhibition for developing novel cancer therapies, announced the completion of patient enrollment in its ongoing Phase 2 CRDF-004 trial. This study is evaluating the effectiveness of onvansertib combined with standard-of-care treatment for first-line RAS-mutated metastatic colorectal cancer (mCRC).

  • In February 2025, Pfizer’s combination therapy for metastatic colorectal cancer (mCRC) successfully met one of its primary objectives—improving progression-free survival (PFS)—in a Phase III clinical trial, strengthening its potential for full regulatory approval. The BREAKWATER trial (NCT05217446), an open-label, active-controlled study, evaluated a treatment regimen combining Pfizer’s Braftovi (encorafenib), Eli Lilly’s Erbitux (cetuximab), and the chemotherapy regimen mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin). The trial focused on treatment-naive mCRC patients with a BRAF V600E mutation.

  • In February 2025, Averto Medical announced that its ColoSeal™ Intraluminal Colonic Diversion (ICD) System has received Breakthrough Device Designation from the FDA. This groundbreaking device aims to improve recovery and outcomes for patients undergoing colorectal surgery by potentially removing the need for a temporary ostomy.

  • In January 2025, The FDA has approved Amgen’s KRAS G12C inhibitor, Lumakras, for use in combination with Vectibix to treat advanced colorectal cancer. Additionally, in December 2024, EndoQuest Robotics received FDA IDE approval to initiate a clinical trial assessing its surgical robot for the removal of colorectal lesions. The study, involving 50 participants across five sites in the US, will evaluate the robot’s safety and effectiveness in performing endoscopic submucosal dissection (ESD) procedures (NCT06133387).

  • In November 2024, Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has released initial clinical data from its ongoing Phase 1C trial. The study evaluates vilastobart (XTX101), a tumor-activated, Fc-enhanced, high-affinity anti-CTLA-4, in combination with atezolizumab (Tecentriq®) for patients with advanced solid tumors and colorectal cancer.

  • In September 2024, FRUZAQLA® (fruquintinib) is a kinase inhibitor approved for treating adults with metastatic colorectal cancer (mCRC). This novel oral targeted therapy is designed for once-daily use, providing a non-chemotherapy alternative for patients who have previously received treatments such as fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, along with anti-vascular endothelial growth factor (VEGF) therapy.

  • In January 2024, Bristol Myers Squibb (BMS) recently disclosed encouraging findings from the Phase III CheckMate -8HW study involving Opdivo (nivolumab) and Yervoy (ipilimumab) as an initial treatment choice for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). This open-label, randomized Phase III trial aims to assess the effectiveness of combining Opdivo and Yervoy compared to the chemotherapy selected by the investigator.

 

Colorectal Cancer Overview

Colorectal cancer, also known as bowel cancer or colon cancer, refers to cancer that develops in the colon or rectum, which are parts of the digestive system. It typically starts as small, noncancerous clumps of cells called polyps that form on the inner lining of the colon or rectum. Over time, some of these polyps can become cancerous.

 

Get a Free Sample PDF Report to know more about Colorectal Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight

 

Emerging Colorectal Cancer Drugs Under Different Phases of Clinical Development Include:

  • 188RNL-BAM: Plus Therapeutics

  • PCS11T: Processa Pharmaceuticals

  • HLX13: Shanghai Henlius Biotech

  • Adagrasib: Mirati Therapeutics

  • XL092: Exelixis

  • EO2040: Enterome

  • Etrumadenant: Arcus Biosciences

  • LYL845: Lyell Immunopharma

  • Geptanolimab: Apollomics

  • HDM201: Novartis Pharmaceuticals

  • TP-1454: Sumitomo Pharma Oncology

  • NT219: Purple Biotech Ltd.

  • NKTR-255: Nektar Therapeutics

  • Evorpacept (ALX148): ALX Oncology Inc.

  • CPGJ 602 Sunshine: Guojian Pharmaceutical

  • Trastuzumab deruxtecan: Daiichi Sankyo

  • GRT-C901: Gritstone Bio, Inc

  • SHR-1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

  • Trilaciclib: G1 Therapeutics

  • Lumakras (sotorasib): Amgen

  • MRTX849: Mirati Therapeutics

 

Route of Administration

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Colorectal Cancer Pipeline Therapeutics Assessment

  • Colorectal Cancer Assessment by Product Type

  • Colorectal Cancer By Stage and Product Type

  • Colorectal Cancer Assessment by Route of Administration

  • Colorectal Cancer By Stage and Route of Administration

  • Colorectal Cancer Assessment by Molecule Type

  • Colorectal Cancer by Stage and Molecule Type

 

DelveInsight’s Colorectal Cancer Report covers around 200+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Colorectal Cancer product details are provided in the report. Download the Colorectal Cancer pipeline report to learn more about the emerging Colorectal Cancer therapies

 

Some of the key companies in the Colorectal Cancer Therapeutics Market include:

Key companies developing therapies for Colorectal Cancer are – Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others.

 

Colorectal Cancer Pipeline Analysis:

The Colorectal Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Colorectal Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer Treatment.

  • Colorectal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Colorectal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Colorectal Cancer drugs and therapies

 

Colorectal Cancer Pipeline Market Drivers

  • Emergence of targeted therapies for mCRC treatment, technical Advancement in molecular subtyping of CRC tumors, increase in product development activities are some of the important factors that are fueling the Colorectal Cancer Market.

 

Colorectal Cancer Pipeline Market Barriers

  • However, limitations in understanding secondary resistance, high Cost of Treatment • Challenges related to precision oncology in mCRC management and other factors are creating obstacles in the Colorectal Cancer Market growth.

 

Scope of Colorectal Cancer Pipeline Drug Insight

  • Coverage: Global

  • Key Colorectal Cancer Companies: Plus Therapeutics, Processa Pharmaceutic als, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmace uticals Co., Ltd., G1 Therapeutics, Amgen, Mirati Therapeutics, and others

  • Key Colorectal Cancer Therapies: 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR, 255, Evorpacept (ALX148), CPGJ 602 Sunshine, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others

  • Colorectal Cancer Therapeutic Assessment: Colorectal Cancer current marketed and Colorectal Cancer emerging therapies

  • Colorectal Cancer Market Dynamics: Colorectal Cancer market drivers and Colorectal Cancer market barriers

 

Request for Sample PDF Report for Colorectal Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1

Colorectal Cancer Report Introduction

2

Colorectal Cancer Executive Summary

3

Colorectal Cancer Overview

4

Colorectal Cancer- Analytical Perspective In-depth Commercial Assessment

5

Colorectal Cancer Pipeline Therapeutics

6

Colorectal Cancer Late Stage Products (Phase II/III)

7

Colorectal Cancer Mid Stage Products (Phase II)

8

Colorectal Cancer Early Stage Products (Phase I)

9

Colorectal Cancer Preclinical Stage Products

10

Colorectal Cancer Therapeutics Assessment

11

Colorectal Cancer Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Colorectal Cancer Key Companies

14

Colorectal Cancer Key Products

15

Colorectal Cancer Unmet Needs

16

Colorectal Cancer Market Drivers and Barriers

17

Colorectal Cancer Future Perspectives and Conclusion

18

Colorectal Cancer Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Colorectal Cancer Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma, Shanghai Henlius

Merkel Cell Carcinoma Pipeline Outlook Report 2025: Key 14+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Merkel Cell Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Merkel Cell Carcinoma pipeline landscape. It covers the Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Merkel Cell Carcinoma Pipeline Outlook Report

Key Takeaways from the Merkel Cell Carcinoma Pipeline Insights Report

  • In August 2025, Incyte Corporation announced a study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
  • In August 2025, Replimune Inc. conducted a Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. The study will enroll a total of 65 evaluable patients.
  • DelveInsight’s Merkel Cell Carcinoma pipeline report depicts a robust space with 14+ active players working to develop 14+ pipeline therapies for Merkel Cell Carcinoma treatment.
  • The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
  • Promising Merkel Cell Carcinoma Therapies such as Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.

Learn how leading Merkel Cell Carcinoma Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Merkel Cell Carcinoma Clinical Trials Assessment

Merkel Cell Carcinoma Emerging Drugs Profile

  • Domatinostat: 4SC

Domatinostat is an orally administered histone deacetylase (HDAC) inhibitor with a unique mode of action that was designed to strengthen the body’s own anti-tumor immune response. Domatinostat “opens” the tumor microenvironment and encourages infiltration of immune cells into the tumor. To advance the development program, 4SC has also signed a drug supply agreement with Merck KGaA for avelumab (anti-PD-L1 antibody) to conduct a Phase II clinical trial of domatinostat in combination with avelumab in advanced-stage Merkel cell carcinoma (MCC) patients progressing on previous anti-PD-(L)1 monotherapy (MERKLIN 2).

  • Cavrotolimod: Exicure

Cavrotolimod (AST-008) is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. During the first half of 2019, five clinical trial sites were opened and began dosing patients for the Phase I/II clinical trial. The Phase 1b stage was an open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod (AST-008) injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors. The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). Exicure initiated the Phase II stage of the clinical trial with dose-expansion cohorts of intratumoral cavrotolimod in combination with approved checkpoint inhibitors to treat two cohorts of patients with locally advanced or metastatic MCC or CSCC.

The Merkel Cell Carcinoma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Merkel Cell Carcinoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Merkel Cell Carcinoma Treatment.
  • Merkel Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Merkel Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Merkel Cell Carcinoma market.

Explore the dynamic world of drug development with our latest Merkel Cell Carcinoma Pipeline Insights report! Don’t miss this opportunity to stay informed—download now! @ Merkel Cell Carcinoma Treatment Drugs

Merkel Cell Carcinoma Companies

ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.

Merkel Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Merkel Cell Carcinoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Stay updated with the latest Merkel Cell Carcinoma Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Merkel Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Merkel Cell Carcinoma Companies- ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
  • Merkel Cell Carcinoma Therapies- Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.
  • Merkel Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Merkel Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which Merkel Cell Carcinoma Companies are leading the way in drug discovery? Download now to stay at the forefront of pharmaceutical innovation!” @ Merkel Cell Carcinoma Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Merkel Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Mid Stage Products (Phase II)
  7. Domatinostat: 4SC
  8. Drug profiles in the detailed report…..
  9. Early Stage Products (Phase I/II)
  10. XmAb18087: Xencor
  11. Drug profiles in the detailed report…..
  12. Preclinical stage products
  13. SNS-401-NG: Sensei Biotherapeutics
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Merkel Cell Carcinoma Key Companies
  17. Merkel Cell Carcinoma Key Products
  18. Merkel Cell Carcinoma- Unmet Needs
  19. Merkel Cell Carcinoma- Market Drivers and Barriers
  20. Merkel Cell Carcinoma- Future Perspectives and Conclusion
  21. Merkel Cell Carcinoma Analyst Views
  22. Merkel Cell Carcinoma Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/merkel-cell-carcinoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Merkel Cell Carcinoma Pipeline Outlook Report 2025: Key 14+ Companies and Breakthrough Therapies Shaping the Future Landscape

HER2-Negative Breast Cancer Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “HER2-Negative Breast Cancer Pipeline Insight” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-Negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive HER2-Negative Breast Cancer Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ HER2-Negative Breast Cancer Pipeline Outlook Report

Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report

  • In August 2025, RayzeBio, Inc. announced a Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
  • In August 2025, AstraZeneca conducted a study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.
  • DelveInsight’s HER2-Negative Breast Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for HER2-Negative Breast Cancer treatment.
  • The leading HER2-Negative Breast Cancer Companies such as Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.
  • Promising HER2-Negative Breast Cancer Therapies such as Doxorubicin, Cyclophosphamide, Utidelone Combined with Bevacizumab, Capecitabine, Carboplatin, Cisplatin, and others.

Discover how the HER2-Negative Breast Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth HER2-Negative Breast Cancer Pipeline Analysis for a closer look at promising breakthroughs @ HER2-Negative Breast Cancer Clinical Trials and Studies

HER2-Negative Breast Cancer Emerging Drugs Profile

  • Giredestrant : Genentech

Giredestrant is a novel investigative small molecule that works as selective estrogen receptor degrader (SERD) by targeting the estrogen receptor (ER). The drug candidate is a new molecular entity (NME) which is administered through oral route. Preclinical studies suggest that Giredestrant is orally bioavailable and competitively inhibits the binding of estrogen to the ER. In preclinical models, Giredestrant has been shown to restrain the normally dynamic behavior of both wild-type and mutant ER, immobilizing the ER and attenuating the expression of its target genes. Currently, the drug is in Phase III stage of its development for the treatment of HER2 negative breast cancer.

  • Inavolisib : Genentech

Inavolisib is an investigational small molecule designed to selectively inhibit mutant PI3Kα. In preclinical models, the molecule showed potent selective inhibition of PI3Kα and has increased potency to mutant PI3K cells over wild type. It is less sensitive for the other three PI3K isoforms. Inavolisib binds to the ATP-binding site of PI3Kα, thereby blocking phosphorylation of PIP2 to PIP3 and preventing downstream signaling as shown in preclinical models. Moreover, inavolisib specifically degrades the mutant form of PI3Kα, resulting in reduction of pathway activity. Currently the drug is in Phase III stage of its development for the treatment of HER2 negative breast cancer.

  • CX-2009 : CytomX Therapeutics

CX-2009 (Praluzatamab ravtansine) is a conditionally activated antibody-drug conjugate (ADC) comprised of a CD166-directed humanized monoclonal antibody conjugated to the maytansinoid DM4, a tubulin inhibitor. Praluzatamab ravtansine utilizes CytomX Probody® platform technology, which incorporates a masking peptide to cover and block the cellular binding region of the antibody. Tethered to the antibody via a protease-cleavable linker, currently, the drug is in Phase II stage of its development for the treatment of HER2 negative breast cancer.

  • H3B 6545 : H3 Biomedicine

H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer. H3B- 6545, a first-in-class small molecule selective estrogen receptor covalent antagonist (SERCA) demonstrates activity in tumor models that harbor wild-type or mutant ERα.4 H3B-6545 activity against ERα mutants resistant to standard therapy provides an opportunity to target a currently unmet medical need both as a single agent and in combination with other breast cancer therapies. Currently, the drug is in Phase II stage of its development for the treatment of HER2 negative breast cancer.

  • RGT-419B : Regor Therapeutics

RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. Results from non-clinical studies showed that RGT-419B demonstrated full suppression of ER+ breast cancer cell proliferation with acquired resistance to CDK4/6 inhibitors. Additionally, RGT-419B’s tumor cell suppression was further augmented when combined with a selective estrogen receptor down-regulator or a PI3K signaling pathway inhibitor. Currently, the drug is in Phase I stage of its development for the treatment of HER2 negative breast cancer.

The HER2-Negative Breast Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of HER2-Negative Breast Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2-Negative Breast Cancer Treatment.
  • HER2-Negative Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • HER2-Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2-Negative Breast Cancer market.

Get a detailed analysis of the latest innovations in the HER2-Negative Breast Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ HER2-Negative Breast Cancer Unmet Needs

HER2-Negative Breast Cancer Companies

Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.

HER2-Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

HER2-Negative Breast Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming HER2-Negative Breast Cancer Therapies and key HER2-Negative Breast Cancer Developments @ HER2-Negative Breast Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the HER2-Negative Breast Cancer Pipeline Report

  • Coverage- Global
  • HER2-Negative Breast Cancer Companies- Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.
  • HER2 Negative Breast Cancer Therapies- Doxorubicin, Cyclophosphamide, Utidelone Combined with Bevacizumab, Capecitabine, Carboplatin, Cisplatin, and others.-
  • HER2-Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • HER2-Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in HER2-Negative Breast Cancer drug development? Find out in DelveInsight’s exclusive HER2-Negative Breast Cancer Pipeline Report—access it now! @ HER2-Negative Breast Cancer Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. HER2 Negative Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. HER2 Negative Breast Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Giredestrant : Genentech
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CX-2009 : CytomX Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. RGT-419B : Regor Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. HER2 Negative Breast Cancer Key Companies
  21. HER2 Negative Breast Cancer Key Products
  22. HER2 Negative Breast Cancer- Unmet Needs
  23. HER2 Negative Breast Cancer- Market Drivers and Barriers
  24. HER2 Negative Breast Cancer- Future Perspectives and Conclusion
  25. HER2 Negative Breast Cancer Analyst Views
  26. HER2 Negative Breast Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/her2-negative-breast-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2-Negative Breast Cancer Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping the Future Landscape

Metastatic Melanoma Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Metastatic Melanoma Pipeline Insight, 2025” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Melanoma pipeline landscape. It covers the Metastatic Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Metastatic Melanoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Metastatic Melanoma Pipeline Outlook

Key Takeaways from the Metastatic Melanoma Pipeline Report

  • In August 2025, Replimune Inc. announced a study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
  • In August 2025, Georgiamune Inc. conducted a GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
  • DelveInsight’s Metastatic Melanoma pipeline report depicts a robust space with 75+active players working to develop 75+ pipeline therapies for Metastatic Melanoma treatment.
  • The leading Metastatic Melanoma Companies such as TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others.
  • Promising Metastatic Melanoma Pipeline Therapies such as TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others

Stay ahead with the most recent pipeline outlook for Metastatic Melanoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Melanoma Treatment Drugs

Metastatic Melanoma Emerging Drugs

  • EVX 01: Evaxion Biotech

EVX-01, is a novel personalized cancer immunotherapy based on Evaxion’s proprietary PIONEER™ AI technology. EVX-01 is safe and has encouraging early indications of clinically and meaningful antitumor activity. Data showed EVX-01 is capable of eliciting T-cell responses in a clinical setting where the patients received concurrent standard immune therapy, i.e. anti-PD-1 treatment. Results demonstrated an antitumor effect in combination with anti-PD-1 treatment. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.

  • IN 10018: InxMed

IN10018 is a potent and highly selective adenosine triphosphate competitive FAK inhibitor, and InxMed has its exclusive global development and commercial operation rights. Early clinical data on IN10018 showed its safety and efficacy in multiple tumor types, and the latest research results and preclinical data demonstrated that IN10018 can also be effective in combination therapies. It is expected to overcome the tumor-associated fibrosis barrier and improve local immunity, and therefore has the potential to act as an important anchor molecule in synergy with different therapeutic modalities including immunotherapy, chemotherapy, and targeted therapy. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.

  • AV MEL 1: AiVita Biomedical

AV MEL 1, is an investigational drug being developed by AiVita Biomedical. AIVITA has received IND approval to begin a Phase 1B trial investigating its cancer vaccine in patients with metastatic melanoma plus checkpoint inhibitors.

The Metastatic Melanoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.
  • Metastatic Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market

Explore groundbreaking therapies and clinical trials in the Metastatic Melanoma Pipeline. Access DelveInsight’s detailed report now! @ New Metastatic Melanoma Drugs

Metastatic Melanoma Companies

TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO Internationa LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others.

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Metastatic Melanoma Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Unveil the future of Metastatic Melanoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Metastatic Melanoma Market Drivers and Barriers

Scope of the Metastatic Melanoma Pipeline Report

  • Coverage- Global
  • Metastatic Melanoma Companies- TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO Internationa LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others.
  • Metastatic Melanoma Pipeline Therapies- TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others
  • Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Metastatic Melanoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Metastatic Melanoma Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Melanoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Melanoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. EVX 01: Evaxion Biotech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. IN 10018: InxMed
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Melanoma Key Companies
  21. Metastatic Melanoma Key Products
  22. Metastatic Melanoma- Unmet Needs
  23. Metastatic Melanoma- Market Drivers and Barriers
  24. Metastatic Melanoma- Future Perspectives and Conclusion
  25. Metastatic Melanoma Analyst Views
  26. Metastatic Melanoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Melanoma Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape

Ulcerative Colitis Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Ulcerative Colitis Pipeline Insight 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Ulcerative Colitis Treatment Landscape. Click here to read more @ Ulcerative Colitis Pipeline Outlook

Key Takeaways from the Ulcerative Colitis Pipeline Report

  • In August 2025, Sanofi announced phase 2 study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis.
  • In August 2025, Boehringer Ingelheim conducted a study has 2 parts. In Part A, participants get BI 3032950 as an infusion into a vein every 4 weeks. After 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improved. Before the results of this assessment are available, participants move on to Part B and get BI 3032950 as an injection under the skin. Participants whose results show clinical response after 12 weeks can continue treatment with BI 3032950. They get BI 3032950 injections under the skin every 4 weeks for up to 2 years.
  • DelveInsight’s Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment.
  • The leading Ulcerative Colitis Companies such as Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
  • Promising Ulcerative Colitis therapies such as VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.

Discover groundbreaking developments in Ulcerative Colitis therapies! Gain in-depth knowledge of key Ulcerative Colitis clinical trials, emerging drugs, and market opportunities @ Ulcerative Colitis Clinical Trials Assessment

Ulcerative Colitis Emerging Drugs Profile

  • Obefazimod: Abivax

Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis.

  • ABBV-668: AbbVie

ABBV-668 is under development for the treatment of crohn’s disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.

  • TEV-48574: Teva Pharmaceutical

Anti-TL1A (TEV-’574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-’574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-’574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn’s disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-’574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.

  • SOR102: Sorriso Pharmaceuticals

SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis.

The Ulcerative Colitis Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.
  • Ulcerative Colitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market

Stay informed about the Ulcerative Colitis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Ulcerative Colitis Unmet Needs

Ulcerative Colitis Companies

Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.

Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Ulcerative Colitis Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Transform your understanding of the Ulcerative Colitis Pipeline! See the latest progress in drug development and clinical research @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspectives

Scope of the Ulcerative Colitis Pipeline Report

  • Coverage- Global
  • Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
  • Ulcerative Colitis therapies- VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.
  • Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

“Stay Ahead in Gastroenterology Research–Access the Full Ulcerative Colitis Pipeline Analysis Today! @ Ulcerative Colitis Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Ulcerative Colitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Ulcerative Colitis– DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Ulcerative Colitis Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. Mirikizumab: Eli Lilly and Company
  11. Drug profiles in the detailed report…..
  12. Late Stage Products (Phase III)
  13. Obefazimod: Abivax
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. ABBV-668: AbbVie
  17. Drug profiles in the detailed report…..
  18. Early Stage Products (Phase I)
  19. SOR102: Sorriso Pharmaceuticals
  20. Drug profiles in the detailed report…..
  21. Preclinical Stage Products
  22. Drug Name: Company Name
  23. Drug profiles in the detailed report…..
  24. Inactive Products
  25. Ulcerative Colitis Key Companies
  26. Ulcerative Colitis Key Products
  27. Ulcerative Colitis- Unmet Needs
  28. Ulcerative Colitis- Market Drivers and Barriers
  29. Ulcerative Colitis- Future Perspectives and Conclusion
  30. Ulcerative Colitis Analyst Views
  31. Ulcerative Colitis Key Companies
  32. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ulcerative Colitis Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping the Future Landscape

WAVLINK Launches Groundbreaking Thunderbolt 5 Docking Station, Unlocking Unprecedented Connectivity

Shenzhen, China – WAVLINK, a recognized innovator in connectivity solutions, today announced the full market release of its highly anticipated Thunderbolt™ 5 Docking Station. Engineered to meet the escalating demands for bandwidth, versatility, and performance in professional and high-end user environments, the dock represents a significant advancement in peripheral connectivity technology.

This comprehensive docking solution leverages the cutting-edge Thunderbolt 5 standard, offering drastically enhanced data transfer speeds, robust power delivery, and exceptional multi-display support compared to previous generations. The launch signifies WAVLINK’s commitment to pushing the boundaries of device expansion and productivity.

1903

Unmatched Speed and BandwidthAt the core of the WAVLINK Thunderbolt 5 Docking Station is its exceptional throughput, facilitated by a dedicated Thunderbolt 5 upstream port operating at 120Gb/s. This enables the dock to deliver:

  • Blazing-Fast Data Transfer: Three downstream Thunderbolt 5 ports provide data transfer speeds up to 80Gb/s, enabling near-instantaneous movement of large files, seamless 4K/8K video editing workflows, and rapid handling of complex 3D modeling data.

  • High-Power Charging: The upstream port supports Power Delivery (PD) up to 140W, sufficient to charge high-performance laptops. Downstream Thunderbolt ports provide PD at 15W and 30W, facilitating charging for smartphones, tablets, and other accessories simultaneously.

  • Extreme Display Capabilities: The dock dramatically expands visual workspace potential. It supports a single immersive 8K display at 144Hz for unparalleled gaming and cinematic experiences. For multi-tasking professionals, it enables dual 8K displays at 60Hz or triple 4K displays at an ultra-smooth 144Hz, ideal for financial trading, video conferencing, creative content production, and complex data visualization.

Comprehensive Connectivity SuiteBeyond the core Thunderbolt 5 ports, the dock boasts an extensive array of high-speed interfaces designed to connect virtually any peripheral:

  • Network: A 2.5Gbps RJ45 Ethernet port ensures high-speed, stable wired network connectivity crucial for bandwidth-intensive tasks, large file transfers, low-latency online gaming, and uninterrupted video conferencing.

  • USB Expansion: Four USB-A 3.2 Gen ports provide ample connectivity for keyboards, mice, external storage drives, webcams, and other essential peripherals.

  • Media Transfer: A dedicated SD 4.0 card reader (UHS-II compatible) offers professional photographers and videographers a fast and convenient way to transfer high-resolution images and footage directly from cameras.

  • Audio: A combined 3.5mm Audio/Mic jack caters to headset and speaker connectivity.

  • Security: A Kensington lock slot enhances physical security for the dock and the host device in shared or public environments.

Design, Compatibility, and UsabilityThe WAVLINK Thunderbolt 5 Docking Station emphasizes both form and function:

  • Portable Design: Its compact and lightweight profile makes it an ideal travel companion, enabling users to transform any location into a fully equipped workstation.

  • Universal Compatibility: The dock is rigorously tested for broad compatibility, functioning seamlessly with laptops, tablets, and desktops running Windows, macOS, and Linux operating systems. This ensures reliable performance across diverse user ecosystems.

  • User-Centric Experience: The array of ports is strategically positioned for accessibility, simplifying cable management and enhancing the overall user experience whether working from home, the office, or remotely.

Driving the Future of Connectivity

“The launch of our Thunderbolt 5 Docking Station marks a pivotal moment in expanding the horizons of device connectivity,” stated a spokesperson Johnson Huang for WAVLINK “We are dedicated to delivering innovative, high-quality technology solutions that empower users. This dock is engineered to break through the limitations of traditional connections, unlocking the full potential of users’ devices and paving the way for a significantly more efficient and streamlined digital experience.”

Availability

The WAVLINK Thunderbolt 5 Docking Station is now available for purchase through major e-commerce platforms globally and directly via the official WAVLINK online store. WAVLINK anticipates that this advanced docking solution will become integral to the workflows and lifestyles of professionals and technology enthusiasts seeking the highest levels of performance and connectivity.

About WAVLINK

WAVLINK is a technology-driven company specializing in networking, communication systems, and PC peripheral solutions. As an integrated enterprise combining design, R&D, manufacturing, quality control, and global sales, WAVLINK has been deeply rooted in the industry for over a decade.

With a strong reputation for reliability and innovation, WAVLINK has earned the trust of tens of millions of users worldwide, and its global market share continues to grow steadily. The company is committed to pushing the boundaries of cutting-edge technologies and aims to be a leading force in the connectivity industry.

Social Media：

Facebook

Youtube

Tiktok

Media Contact
Company Name: WAVLINK TECHONOLOGY Ltd
Contact Person: Kevin Qiu
Email: Send Email
Country: China
Website: https://www.wavlink.com

Snowflake Trader Launches Mindset-First Trading Framework to Help Traders Build Consistency and Long-Term Success

Snowflake Trader has unveiled a new approach to trading education that focuses on the often-overlooked foundation of market success: mindset and process discipline. By combining a structured Trading Playbook with guided exercises, custom-built tools, and a gradual risk-scaling methodology, the platform aims to help beginner and struggling traders develop the habits necessary for sustainable performance.

While much of the trading education industry emphasizes chart patterns, backtesting, or aggressive strategies, Snowflake Trader addresses what it identifies as the primary cause of failure among traders: the absence of a defined process for risk control and emotional mastery. “We believe that consistent results in trading come from consistent decision-making,” said a spokesperson for Snowflake Trader. “We’ve kept the Playbook, exercises, and many of our tools free and open-source because we believe every trader deserves access to this mindset shift. Our framework teaches traders to master discipline and process before focusing on profit targets.”

A Structured, Low-Risk Path to Trading Mastery

The Snowflake Trader method centers on:

  • Mindset-First Training – Building decision-making habits and market discipline before pursuing aggressive gains.

  • Practical, Proven Tools – Including custom indicators, calculators, and self-assessments created from real-world trading experience.

  • The Trading Playbook – A step-by-step guide explaining the purpose and expected impact of each exercise in the program.

  • Gradual Risk Scaling – Allowing traders to validate their process with minimal capital before increasing position sizes.

  • Customizable Growth – Adapting the process to suit each trader’s style, availability, and personal goals.

Through a series of hands-on exercises, traders can track their own equity curve as a personal proof of progress, transforming trading from a high-risk gamble into a structured and measurable skill-building journey.

Designed for Long-Term Success

Snowflake Trader’s approach is built on the principle that traders who master discipline, patience, and self-awareness are better equipped to thrive in volatile markets. By focusing on process over outcome, the platform aims to create a new generation of traders who treat the markets like a business rather than a lottery.

About Snowflake Trader

Snowflake Trader helps beginner and struggling traders build the right trading mindset—the true foundation of long-term success. Through a unique combination of its Trading Playbook, practical tools, and mindset-first philosophy, the company provides a structured, low-risk pathway to consistent performance in the markets.

For more information, visit www.snowflaketrader.com.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Snowflake Trader
Contact Person: Gurpreet Singh
Email: Send Email
Phone: 15106505738
Country: United States
Website: https://www.snowflaketrader.com/